Entera Bio Ltd.: management transactions · United States · SEC (Form 4)

About Entera Bio Ltd.

Entera Bio Ltd. (NASDAQ: ENTX) is a clinical-stage biotechnology company listed in the United States on the NASDAQ market. Although the company is incorporated as an Israeli entity and its operations are largely centered in Israel, it is a U.S.-listed issuer with public reporting under SEC rules. For international investors, Entera fits the profile of a development-stage biotech: limited or no meaningful product revenue today, a valuation driven primarily by clinical execution, regulatory progress, partnership activity, and the company’s ability to fund its pipeline. Entera was incorporated on September 30, 2009 and commenced operations on June 1, 2010. The company’s core investment thesis is built around an oral delivery platform for peptides and protein replacement therapies. In practical terms, Entera is trying to convert biologic therapies that are typically administered by injection into tablet form. This is a differentiated scientific proposition if it can reliably achieve sufficient bioavailability, safety, and manufacturing consistency. The most advanced assets include EB613, which is being developed for high-risk postmenopausal osteoporosis, and EB612, which targets hypoparathyroidism. Entera is also advancing additional oral peptide programs, including a collaboration with OPKO Health focused on an oral oxyntomodulin / GLP-1 / glucagon candidate for metabolic disease. From a competitive standpoint, Entera operates in a crowded and capital-intensive environment. It competes indirectly with large pharmaceutical companies, specialty endocrinology and metabolism developers, and other peptide-focused biotechs. Its strategic advantage is not scale, but a potentially disruptive formulation platform that could improve patient convenience and adherence if clinical data continue to support the approach. As with most clinical-stage biotech names, the investment case is highly binary: clinical readouts, FDA interactions, intellectual property, partnership structures, and cash runway can materially change the outlook. Recent corporate developments have been notable. Entera reported full-year 2025 results in March 2026 and first-quarter 2026 results in May 2026. It also announced a direct investment by BVF Partners and expanded its OPKO collaboration, which together help support funding and pipeline progression. Another key update was FDA alignment on a phase 3 study design for EB613, including the use of total hip BMD as the primary endpoint, which may reduce regulatory uncertainty around the program. Overall, Entera Bio remains a speculative but scientifically interesting NASDAQ-listed U.S. biotech name with upside tied to oral peptide development and execution across clinical and financing milestones.